<DOC>
	<DOCNO>NCT02724423</DOCNO>
	<brief_summary>This study evaluate pharmacokinetic safety NRL-1 epilepsy subject . Subjects receive single intranasal dose NRL-1 either 5 mg , 10 mg , 15 mg 20 mg base subject 's body weight .</brief_summary>
	<brief_title>Repeat-Dose Pharmacokinetics Study NRL-1 Epilepsy Subjects</brief_title>
	<detailed_description>Diazepam rectal gel ( Diastat ) formulation diazepam indicate management select , refractory patient epilepsy stable regimen antiepileptic drug ( AEDs ) require intermittent use diazepam control bout increase seizure activity , i.e. , Acute Repetitive Seizures ( ARS ) . A diazepam nasal spray develop patient experience ARS provide alternative convenient acceptable route diazepam administration .</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<criteria>1 . Male female subject age 6 65 year , inclusive . 2 . Written inform consent participate study . 3 . Body mass index ( BMI ) exceed 35 kg/m² , inclusive . 4 . Subject clinical diagnosis Epilepsy schedule admit Epilepsy Monitoring Unit ( EMU ) extracranial videoElectroencephalogram ( EEG ) record seizure event evaluation Epilepsy , opinion Investigator , may need benzodiazepine intervention seizure control . 5 . Subjects either partial generalized Epilepsy motor seizures seizure clear alteration awareness eligible enrollment . 6 . Female subject childbearing potential , defined menstrual cycle surgically sterile less two ( 2 ) year postmenopausal , must complete pregnancy screen agree utilize one follow form contraception trial 21 day last dose study drug : abstinence , hormonal ( oral , transdermal , implant , injection ) , barrier ( condom , diaphragm spermicide ) , intrauterine device ( IUD ) , vasectomized partner ( six month minimum ) . 7 . No clinically significant abnormal finding medical history , physical examination , ECG ( correct QT interval [ QTcF ] &lt; 450 msec male QTcF &lt; 470 msec female ) , clinical laboratory result screen . 8 . Subjects caregiver must agree return study site study visit must willing comply require study procedure . 1 . Subject undergoing intracranial EEG monitoring . 2 . A history clinically significant gastrointestinal , renal , hepatic , neurologic , hematologic , endocrine , oncologic , pulmonary , immunologic , psychiatric , cardiovascular disease , severe seasonal nonseasonal allergy , nasal polyp nasal passage abnormality could interfere nasal spray administration , condition , opinion Investigator , would jeopardize safety subject impact validity study result . 3 . Subject significant traumatic injury , major surgery open biopsy within 30 day prior study screen . 4 . Subjects active major depression past suicide attempt document Baseline/Screening CSSRS . The child CSSRS use subject age 6 11 . The adult CSSRS use subject 12 great year age . 5 . Any Suicidal Ideation 3 , 4 , 5 Suicidal Behavior Lifetime use CSSRS . 6 . A history allergic adverse response diazepam comparable similar product . 7 . Subjects ( whatever reason ) abnormal diet ( one severely restrict specific basic food group [ e.g. , ketogenic diet ] , limit calorie [ e.g. , fast ] , and/or require use daily supplement substitute food typically eat mealtime ) , four ( 4 ) week precede study . 8 . Subjects donate blood plasma within 30 day first dose study drug . 9 . Participation clinical trial within 30 day prior first dose study drug . Participation observational ( noninterventional ) study exclude long scheduling conflict study . 10 . Inadequate difficult venous access may jeopardize quality time PK sample . 11 . Female subject try conceive , pregnant , lactate . 12 . Positive serum pregnancy test ( ßhCG ) screen urine pregnancy test prior administration study drug woman childbearing potential . 13 . Positive blood screen subject age 12 great human immunodeficiency virus ( HIV ) , Hepatitis B surface antigen ( HbSAg ) , Hepatitis C , positive urine screen alcohol , drug abuse , cotinine . When marijuana use medical reason opinion investigator , consider drug abuse patient enrol even marijuana metabolite urine reveal positive . 14 . Treatment phenobarbital primidone within 30 day anticipate dose visit ( i.e. , baseline ) . 15 . Treatment warfarin dabigatran blood thinner within 30 day anticipate dose visit ( i.e. , baseline ) . 16 . Treatment diazepam contain product within 14 day anticipate dose visit ( i.e. , baseline ) . 17 . Use nasal decongestant nasal steroid within 7 day prior screen visit study . 18 . Subject flu , rhinitis nasal condition would impact absorption intranasal diazepam .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>epilepsy</keyword>
	<keyword>seizure</keyword>
</DOC>